Zorn v. U.S. Department of Justice

District Court, District of Columbia·Decided January 6, 2025·No. Civil Action No. 2024-3360·Published

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

MATTHEW C. ZORN, Plaintiff,

v. Case No. 24-cv-03360 (CRC)

U.S. DEPARTMENT OF JUSTICE, DRUG ENFORCEMENT ADMINISTRATION,

Defendants.

MEMORANDUM OPINION AND ORDER Marijuana legalization has long divided the public. Apparently, it also divides the current Administration. In October 2022, President Biden directed federal agencies to reevaluate marijuana’s regulatory status under the Controlled Substances Act. After further deliberations within the executive branch, the Attorney General signed a notice of proposed rulemaking to reschedule marijuana and thereby reduce some of the legal restrictions on its use. According to press reporting, the Attorney General signed the notice over the objections of the Drug Enforcement Administration (“DEA”). Before the proposed rulemaking was made public, someone affiliated with a group opposed to rescheduling marijuana posted on social media that the DEA Administrator had not signed off on it. When asked how he knew of this fact ahead of the proposal’s release, the person quipped that he had “friends in low places.”

Attorney Matthew Zorn, who represents parties involved in the rulemaking, took those posts to mean that DEA employees had improperly leaked word of the Administrator’s recalcitrance. Zorn filed a request under the Freedom of Information Act (“FOIA”) seeking DEA emails related to any potential leaks, and now seeks a preliminary injunction ordering the agency to immediately process his request. The Court will deny Zorn’s motion because he has

not demonstrated irreparable harm, his request is overly burdensome, and the equities do not support granting extraordinary relief. I. Background A. Rescheduling Marijuana Under the Controlled Substances Act, substances are classified under one of five “schedules.” See 21 U.S.C. § 812. Drugs in Schedule I are subject to the strictest regulations while those in Schedule V are subject to the least strict. See generally id. §§ 821–32, 841–65, 951–71. Marijuana is a Schedule I substance, a classification for drugs that do not have any “currently accepted medical use in treatment in the United States.” Id. § 812(b)(1)(B), (c).

Lamenting “our failed approach to marijuana,” in 2022, President Biden directed the Department of Justice and the Department of Health and Human Services to reevaluate the drug’s classification. Statement from President Biden on Marijuana Reform, The White House (Oct. 6, 2022), https://perma.cc/L9K7-C26D. About a year and a half later, the Department of Justice formally proposed rescheduling marijuana from Schedule I to Schedule III. Schedules of Controlled Substances: Rescheduling of Marijuana, 89 Fed. Reg. 44597, 44597 (May 21, 2024). The Attorney General, rather than the DEA Administrator, signed the notice of proposed rulemaking. See id. at 44622. According to press reporting, DEA has “long resisted” rescheduling marijuana. Joshua Goodman & Jim Mustian, Top U.S. Drug Agency A Notable Holdout in Biden’s Push to Loosen Federal Marijuana Restrictions, AP (May 20, 2024), https://apnews.com/article/marijuana-pot-dea-legalization-biden- cb7869d3286094f0124de728320d89c1.

Following the rulemaking notice, the DEA appointed an administrative law judge to oversee a formal rulemaking process and named a 25-member panel of marijuana groups and

experts to participate in the hearings. Mot. at 4. That panel includes Smart Approaches to Marijuana (“SAM”), a group opposed to rescheduling. Id. at 3. Hearings are scheduled to begin on January 21, 2025, and run through March 6, 2025. Mot. Reply, Ex. 7 at 6.

B. Zorn’s FOIA Request About one week before DOJ published notice of the proposed rulemaking, Dr. Kevin Sabet, who is affiliated with SAM, posted on social media that the DEA Administrator “did NOT sign the rescheduling order, breaking with five decades of precedent and established law and regulations[.]” Mot. at 3. As support, Dr. Sabet cited “two confidential sources inside DEA and another outside DEA[.]” Id. When someone asked Dr. Sabet how he knew about the Administrator’s refusal in advance, he posted that he had “friends in low places.” Id.

Rescheduling proponents took these posts to mean that someone at DEA had engaged in improper ex parte contacts with Dr. Sabet. Two groups raised this issue with the presiding ALJ and asked him to “remov[e] the DEA and its Administrator as the sponsor and proponent of the proposed rescheduling action” and for other relief. Compl., Ex. 3 at 1–2. The ALJ denied that motion, explaining that while he found the allegations “distasteful,” he lacked authority to grant the relief sought. Id. at 2. The ALJ also viewed the record as insufficient to conclude that “the agency’s decisonmaking process has been or would be irrevocably tainted so as to make the ultimate judgment of the agency unfair[.]” Id. at 7 (cleaned up).

Zorn tried a different approach and filed a FOIA request with DEA seeking emails related to the purported contacts. Specifically, he requested all DEA emails between October 1, 2022, and October 29, 2024, with the following keywords:

1. Marijuana; AND 2. Rescheduling or proceeding; AND

3. Sabet OR “smart approaches for marijuana” OR SAM OR Torridon OR Niforatos OR kevin OR barr OR shea

Mot. at 4–5. (“Torridon,” “Niforatos,” “Barr,” and “Shea” refer to other individuals or entities affiliated with SAM. Opp’n at 3–4.) After DEA did not respond, Zorn filed this lawsuit and moved for a preliminary injunction. DEA then denied Zorn’s FOIA request and opposed the preliminary injunction on the ground that Zorn’s initial request was unduly burdensome. Id. at 1–2. In response, Zorn proposed narrowing his FOIA request to emails “from those DEA employees engaged in the ex parte contacts.” Mot. Reply at 2.

The government then moved for summary judgment and filed a declaration supporting its undue-burden arguments. Because Zorn has filed an amended complaint, the Court will deny the government’s motion as moot and permit the government to file another responsive pleading within 30 days of the amended complaint. The Court will, however, construe the government’s motion as a sur-reply for purposes of Zorn’s preliminary-injunction motion and consider the arguments contained therein and the supporting declaration. See 11A Fed. Prac. & Proc. Civ. § 2949 (“Affidavits are appropriate on a preliminary-injunction motion and typically will be offered by both parties.”). II. Legal Standard “A preliminary injunction is an extraordinary remedy never awarded as of right.” Winter v. Nat. Res. Def. Council, 555 U.S. 7, 24 (2008). A party seeking such relief must, “by a clear showing, carr[y] the burden of persuasion” and demonstrate “(1) a substantial likelihood of success on the merits, (2) that it would suffer irreparable injury if the injunction were not granted, (3) that an injunction would not substantially injure other interested parties, and (4) that

the public interest would be furthered by the injunction.” Chaplaincy of Full Gospel Churches v. England, 454 F.3d 290, 297 (D.C. Cir. 2006); Winter, 555 U.S. at 20. The last two factors merge when the government is a party. Nken v. Holder, 556 U.S. 418, 435 (2009).

Free access — add to your briefcase to read the full text and ask questions with AI

Zorn v. U.S. Department of Justice, (D.D.C. 2025).

Zorn v. U.S. Department of Justice (Zorn v. U.S. Department of Justice) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related